Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a leading clinical-stage pharmaceutical company that primarily focuses on the development and commercialization of unique drugs designed to specifically treat inflammatory diseases, fibrotic diseases, and cancer. The company is at the forefront of pioneering innovative therapies that improve the lives of those living with severe, chronic, and life-threatening diseases.
Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals Holdings, Inc. operates through its single segment, which is Research and Development. Its commitment to provide cutting-edge solutions to global health challenges has placed it among the leading organizations in the pharmaceutical industry.
CRBP's flagship product candidate is Lenabasum, a synthetic, oral, small-molecule cannabinoid receptor type 2 (CB2) agonist that the company is studying with the aim to resolve chronic inflammation and halt fibrotic processes without causing weak immune responses. Clinical trials of Lenabasum are currently underway for treating diseases such as systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Apart from Lenabasum, Corbus also has a significant pipeline of other preclinical drug candidates, such as CRB-4001, a second-generation, peripherally-restricted, CB1 inverse agonist. This drug is specifically targeted at metabolic disorders, including nonalcoholic steatohepatitis (NASH) and type-1 diabetes.
Corbus places a high premium on collaborations and partnerships to advance its proprietary drug development. It has forged alliances with institutions such as the Cystic Fibrosis Foundation and the University of Massachusetts Medical School. These strategic collaborations are aimed to promote the development of novel drug candidates, leverage external expertise, and facilitate clinical studies.
While Corbus faces considerable competition in the pharmaceutical industry, its relentless pursuit for breakthrough drugs and commitment to contributing to better healthcare distinguished it in thefield of innovative therapeutic targets. The company continues to focus on advancing its research and clinical programs, with the goal of delivering safe, effective, and approved drugs that can meaningfully improve the overall quality of life for patients suffering from debilitating diseases.
Despite the inherent risks and uncertainties associated with drug development, Corbus Pharmaceuticals Holdings, Inc. has demonstrated resilience and adaptability, underlining its dedication to its mission. Its ground-breaking work continues to unlock potential therapeutic benefits, ensuring that Corbus remains a significant player in the pharmaceutical industry.